Thursday 7 May, 2026
Introduction: Clinical studies combining molecularly-targeted drugs with radiotherapy (RT) have largely failed to improve patient outcomes in cancer. A potential…
Read morePoster: Drug/Disease Modelling - Oncology
INTEGRATED POPULATION SEMI-MECHANISTIC PK/PD MODELING OF HIGH-DOSE METHOTREXATE AND 6-MERCAPTOPURINE EFFECTS ON NEUTROPHIL DYNAMICS IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA
Thursday 7 May, 2026
Introduction/objectives: High-dose methotrexate (HDMTX) is integral to pediatric acute lymphoblastic leukemia (ALL) consolidation therapy but exhibits high variability in exposure…
Read moreAN IN-SILICO APPROACH TO SUPPORT THE ANTIBODY DRUG CONJUGATE (ADC) COMBINATIONS TRIAL DESIGN: IMPACT OF PROPHYLACTIC RESCUE ON EFFICACY
Thursday 7 May, 2026
Introduction & Objectives: Antibody Drug Conjugates (ADCs) have shown reasonable success in several cancer indications in the last decade. However,…
Read moreJoint modeling of tumor size and circulating tumor DNA dynamics to predict overall survival in non-small cell lung cancer
Thursday 7 May, 2026
Objectives: Tumor size-overall survival (TS-OS) modeling is an established approach for predicting OS in oncology clinical trials and thus supporting…
Read moreMECHANISTIC MODELLING OF CRS IN T CELL ENGAGERS – AN APPLICATION FOR BLINATUMOMAB
Thursday 7 May, 2026
Introduction: Blinatumomab is a bispecific T-cell engager (TCE) antibody that simultaneously binds CD3 on T-cells and CD19 on B-cells, thereby…
Read moreModel Based Meta-Analysis of Disease-Free Survival in Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Treated with Mitomycin C or Gemcitabine
Thursday 7 May, 2026
Introduction: Intermediate risk non-muscle invasive bladder cancer (IR-NMIBC) is a heterogeneous disease with variable clinical outcomes, making selection of appropriate…
Read moreElranatamab Exposure-Safety Analysis in Patients with Relapse or Refractory Multiple Myeloma: Insights from MagnetisMM Studies
Thursday 16 October, 2025
Introduction: Elranatamab (ELRA) is a heterodimeric humanized bispecific antibody approved for treatment of patients with relapsed/refractory multiple myeloma (RRMM). ELRA…
Read moreDevelopment of QSP platform model for predicting clinical efficacy and CRS incidence of CD3 bispecifics in STEAP1 Prostate Cancer
Thursday 16 October, 2025
Introduction: CD3 bispecifics are engineered antibodies that bind CD3 on T cells and target antigens on cancer cells (TAAs), activating…
Read moreModelling of tumour growth with respect to the use of anti-cancer agents
Thursday 16 October, 2025
Objectives: This project aimed to compare the performance of models recently published in the literature that characterise tumour volume over…
Read moreOrgan-specific tumor dynamics predict survival of patients with metastatic colorectal cancer
Thursday 16 October, 2025
Objectives: Several tumor growth inhibition (TGI) models have been developed to evaluate the longitudinal trajectories of tumor size and their…
Read more